1-4 of 4
Dominick Lamonica
Close
Sort by
Journal Articles

Disease Control Affects Outcomes of Patients with Relapsed Diffuse Large B Cell Lymphoma Treated with CD19 Directed CAR T-Cell Therapy

Dorothy C Pan, Showkat Hamid, Megan Herr, Kristopher Attwood, Philip L. McCarthy, Maureen Ross, Grant Schofield, Matthew J Cortese, Dominick Lamonica, Jerry Thwin Wong, Kai Fu, Peter Maslak, Marco Davila, Renier Brentjens, Francisco J. Hernandez-Ilizaliturri
Journal: Blood
Blood (2023) 142 (Supplement 1): 7376.
https://doi.org/10.1182/blood-2023-187631
Published: 2023
Journal Articles

Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup

Myron S. Czuczman, MD, Andre Goy, MD, Dominick Lamonica, MD, Daniel A. Graf, MD MPH, Mihaela C. Munteanu, MS, Richard H. van der Jagt, MD FRCP(C)
Journal: Blood
Blood (2014) 124 (21): 1757.
https://doi.org/10.1182/blood.V124.21.1757.1757
Published: 2014
Journal Articles

Open-Label Bendamustine Combined with Rituximab for Treatment of Relapsed/Refractory Mantle-Cell Lymphoma: Efficacy and Safety Findings

Myron S. Czuczman, MD, Dominick Lamonica, MD, Shari K. Gaylor, Leonard Bush, BHS, Penny Nadolny, Dave Colborn
Journal: Blood
Blood (2012) 120 (21): 3662.
https://doi.org/10.1182/blood.V120.21.3662.3662
Published: 2012
Journal Articles

Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication

Theresa Hahn, PhD, Song Yao, Shannon Smiley, Kathleen West, Minoo Battiwalla, Dominick Lamonica, Philip L McCarthy, Jr
Journal: Blood
Blood (2008) 112 (11): 52.
https://doi.org/10.1182/blood.V112.11.52.52
Published: 2008